Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Velcade bortezomib: Phase II; approved in U.S. for multiple myeloma (MM)

MLNM began a U.S. and U.K. open-label Phase II

Read the full 97 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE